Is this a golden age of new drug classes?

This is a very strange and exciting time in drug discovery. Over much of the last 30 years, small molecule drugs have dominated the field, alongside an ever-increasing number of antibodies. Beyond that, the numbers fell off dramatically, and when new drug classes came along, they often had a slow start. Completely new modes of treatment were rare and difficult to realise. The pace has been picking up, though –  I don’t think that so many simultaneous and distinct new approaches have been in development ever before in the history of drug research.